- Home
- INCY vs HTHT Comparison
INCY vs HTHT Comparison
Compare INCY & HTHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- HTHT
- Stock Information
- Founded
- INCY 1991
- HTHT 2005
- Country
- INCY United States
- HTHT China
- Employees
- INCY N/A
- HTHT N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- HTHT Hotels/Resorts
- Sector
- INCY Health Care
- HTHT Consumer Discretionary
- Exchange
- INCY Nasdaq
- HTHT Nasdaq
- Market Cap
- INCY 13.4B
- HTHT 10.9B
- IPO Year
- INCY 1993
- HTHT 2010
- Fundamental
- Price
- INCY $65.06
- HTHT $35.27
- Analyst Decision
- INCY Hold
- HTHT Strong Buy
- Analyst Count
- INCY 19
- HTHT 2
- Target Price
- INCY $72.67
- HTHT $45.00
- AVG Volume (30 Days)
- INCY 1.8M
- HTHT 1.9M
- Earning Date
- INCY 04-29-2025
- HTHT 05-20-2025
- Dividend Yield
- INCY N/A
- HTHT 4.54%
- EPS Growth
- INCY N/A
- HTHT N/A
- EPS
- INCY 0.10
- HTHT 1.42
- Revenue
- INCY $4,413,226,000.00
- HTHT $3,308,482,052.00
- Revenue This Year
- INCY $13.29
- HTHT $7.30
- Revenue Next Year
- INCY $10.43
- HTHT $8.21
- P/E Ratio
- INCY $592.09
- HTHT $24.80
- Revenue Growth
- INCY 17.13
- HTHT 5.86
- 52 Week Low
- INCY $53.56
- HTHT $27.03
- 52 Week High
- INCY $83.95
- HTHT $42.98
- Technical
- Relative Strength Index (RSI)
- INCY 60.01
- HTHT 45.10
- Support Level
- INCY $63.51
- HTHT $35.15
- Resistance Level
- INCY $66.26
- HTHT $36.24
- Average True Range (ATR)
- INCY 1.60
- HTHT 0.96
- MACD
- INCY 0.32
- HTHT -0.21
- Stochastic Oscillator
- INCY 83.12
- HTHT 13.95
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About HTHT H World Group Limited
H World Group Ltd is a multi-brand hotel group in China with international operations. It operates in the leased, manachised, and franchised models. The company has two operating segments; legacy Huazhu and legacy DH. Its brand and product offering includes Economy hotel brands: HanTing Hotel, Ni Hao Hotel, Hi Inn, Elan Hotel, Zleep Hotels, and Ibis Hotel, Midscale hotel brands: JI Hotel, Orange Hotel, Starway Hotel and Ibis Styles Hotel, Upper midscale hotel brands: Crystal Orange Hotel, IntercityHotel, Manxin Hotel, Mercure Hotel, Madison Hotel, Novotel Hotel, CitiGO Hotel and MAXX by Steigenberger, Upscale hotel brands: Joya Hotel, Blossom House, Steigenberger Hotels & Resorts, Jaz in the City, and Grand Mercure; and Luxury hotel brand: Steigenberger Icon and Song Hotels.